Last 11 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Silexion Therapeutics Ltd.'s quarterly P/E stands at 0.0x.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q1 '23 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 0.00 | 0.00 | — | 0.07 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | — | 0.01 | 0.20 | 0.20 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q1 '23 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q1 '23 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | -91.9% | -185.0% | -67.1% | — | — | — | — | — | 0.5% | 0.4% | -0.1% |
| — | — | — | — | — | — | — | — | — | — | — | — | |
| ROA | -405.0% | -37.5% | -35.5% | -31.1% | -58.7% | -422.3% | -48.2% | -32.2% | -31.6% | 0.5% | 0.4% | -0.1% |
| — | +91.1% | +26.3% | +3.5% | -85.7% | -93045.6% | -11093.2% | -38086.1% | — | — | — | — | |
| ROIC | — | — | -1278.4% | — | — | — | — | — | — | -0.8% | -0.5% | — |
| — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 366.6% YoY to 3.97x, strengthening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q1 '23 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | 0.07 | 30.82 | 1.35 | — | — | — | — | — | 0.79 | 0.06 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | 33.60 | 5.12 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 0.64 | 3.97 | 2.44 | 3.22 | 0.64 | 0.85 | 0.98 | 1.72 | 2.27 | 2.25 | 0.06 | 13.00 |
| — | +366.6% | +148.7% | +87.4% | -71.8% | -62.1% | +1526.5% | -86.8% | — | — | — | — | |
| Quick Ratio | 0.64 | 3.97 | 2.44 | 3.22 | 0.64 | 0.85 | 0.98 | 1.72 | 2.27 | 2.25 | 0.06 | 13.00 |
| — | +366.6% | +148.7% | +87.4% | -71.8% | -62.1% | +1526.5% | -86.8% | — | — | — | — | |
| Interest Coverage | -241.75 | — | — | -183.33 | — | -154.54 | -692.50 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 11 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonSilexion Therapeutics Ltd.'s current P/E is 0.0x. The average P/E over the last 2 quarters is 0.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Silexion Therapeutics Ltd.'s business trajectory between earnings reports.